|
|
Blood, 15 May 2008, Vol. 111, No. 10, pp. 5054-5063.
Prepublished online as a Blood First Edition Paper on March 18, 2008; DOI 10.1182/blood-2007-12-130609.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3
Yung-Chi Chang1,
Tse-Ching Chen2,
Chun-Ting Lee1,
Chih-Ya Yang1,
Hsei-Wei Wang1,
Chao-Ching Wang2, and
Shie-Liang Hsieh1,3,4
1 Department and Institute of Microbiology and Immunology, National Yang-Ming University, Taipei;
2 Department of Pathology, Chang Gung Memorial Hospital, Lin-Kou;
3 Genomics Research Center, Academia Sinica, Taipei; and
4 Immunology Research Center, National Yang-Ming University and Taipei Veterans General Hospital, Taipei, Taiwan
Decoy receptor 3 (DcR3) is a member of the TNF receptor superfamily and is up-regulated in tumors originating from a diversity of lineages. DcR3 is capable of promoting angiogenesis, inducing dendritic cell apoptosis, and modulating macrophage differentiation. Since tumor-associated macrophages (TAMs) are the major infiltrating leukocytes in most malignant tumors, we used microarray technology to investigate whether DcR3 contributes to the development of TAMs. Among the DcR3-modulated genes expressed by TAMs, those that encode proteins involved in MHC class II (MHC-II)–dependent antigen presentation were down-regulated substantially, together with the master regulator of MHC-II expression (the class II transactivator, CIITA). The ERK- and JNK-induced deacetylation of histones associated with the CIITA promoters was responsible for DcR3-mediated down-regulation of MHC-II expression. Furthermore, the expression level of DcR3 in cancer cells correlated inversely with HLA-DR levels on TAMs and with the overall survival time of pancreatic cancer patients. The role of DcR3 in the development of TAMs was further confirmed using transgenic mice overexpressing DcR3. This elucidates the molecular mechanism of impaired MHC-II–mediated antigen presentation by TAMs, and raises the possibility that subversion of TAM-induced immunosuppression via inhibition of DcR3 expression might represent a target for the design of new therapeutics.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C.-H. Ho, C.-L. Chen, W.-Y. Li, and C.-J. Chen
Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion
Carcinogenesis,
August 1, 2009;
30(8):
1443 - 1451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Carcinogenesis,
July 1, 2009;
30(7):
1073 - 1081.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mantovani
Cancer-related Inflammation: The Seventh Hallmark of Cancer
ASCO Educational Book,
January 1, 2009;
2009(1):
723 - 726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P.-H. Chen and C.-R. Yang
Decoy Receptor 3 Expression in AsPC-1 Human Pancreatic Adenocarcinoma Cells via the Phosphatidylinositol 3-Kinase-, Akt-, and NF-{kappa}B-Dependent Pathway
J. Immunol.,
December 15, 2008;
181(12):
8441 - 8449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-L. Hsieh
Response: Decoy receptor 3 (DcR3), a pleiotropic immunomodulator
Blood,
August 1, 2008;
112(3):
916 - 917.
[Full Text]
[PDF]
|
|
|
|
|
